‹ ›
MYP_050100
← PREVIOUS NEXT → BACK
Basic Information
Ctry2459
Antimicrobial
Antiviral
Antiviral ▸ Anti-Hepatitis virus ▸ Anti-HCV
Antiviral ▸ Virucidal activity
Enzyme modulation ▸ Enzyme inhibition ▸ Infection inhibition
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Toxic
Venom / Toxin ▸ General toxin ▸ Toxicity
Standard
9 amino acids
C57H83N11O11
Standard
Sequence
FLGFLKNLF
Physicochemical Analysis
1098.34 Da
8.75
0.76
0.55
0.0843
1.33
0.54
0.55
-0.54
130.00
0.3333
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
365.23
0.78
12.0
12.0
35.0
79.0
3.0
9.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0072440 VERIFIED: YES
Provenance & Taxonomy
Chaerilus tryznai [Animal]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HCV Infection inhibition
Hepatitis C virus | 7.5.1 cells
1.675 μM
EC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: 2 min
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. | Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z. | Biomaterials. 2013 Apr;34(13):3511-22. | DOI:10.1016/j.biomaterials.2013.01.075 | PMID:23415044 PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
RECORD: Rec_0081121 VERIFIED: YES
Provenance & Taxonomy
Chaerilus tryznai [Animal]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
Hepatitis C virus
1.84 μg/mL
EC50
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. Biomaterials. 2013 Feb 13;34(13):3511-3522. doi: 10.1016/j.biomaterials.2013.01.075. PMID: 23415044. PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
RECORD: Rec_0094631 VERIFIED: YES
Provenance & Taxonomy
Chaerilus tryznai [Animal]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
Pseudomonas aeruginosa ATCC 9027 or PAO1
45.52-91.04 μM
MIC
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. PMID23415044
RECORD: Rec_0102842 VERIFIED: YES
Provenance & Taxonomy
Chaerilus tryznai [Animal]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral Hemolytic
human red blood cells
Hemolysis
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. Biomaterials. 2013 Feb 13;34(13):3511-3522. doi: 10.1016/j.biomaterials.2013.01.075. PMID: 23415044. PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
RECORD: Rec_0142512 VERIFIED: YES
Provenance & Taxonomy
Chaerilus tryznai [Animal]
Defensin
Structure & Mods
Single-chain peptide backbone represented as a linear sequence entry [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HCV
1.84 μg/mL
EC50
PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records · Page 2 of 4